Top

Head & Neck Oncology

Published in:

Open Access 01-12-2012 | Case report

p16 overexpression in malignant and premalignant lesions of the oral and esophageal mucosa following allogeneic hematopoietic stem cell transplantation

Authors: Yasumasa Kakei, Masaya Akashi, Hideki Komatsubara, Tsutomu Minamikawa, Takahide Komori

Published in: Head & Neck Oncology | Issue 1/2012

Abstract

Objectives

Secondary malignancy in the oral mucosa is recognized as one of the most serious complications in patients who received allogenic hematopoietic stem cell transplantation (HSCT). However, potential risk factors associated with carcinogenesis after HSCT that have been reported remain elusive. We experienced a rare case of secondary malignancies of the oral and esophageal mucosa and analyzed the expression of tumor suppressor gene product p16.

Case report

A 35-year-old male had malignant lesions of the oral and esophageal mucosa two years after HSCT. Partial maxillectomy and endoscopic submucosal dissection were performed. Immunohistochemical analyses revealed that the tumor cells of malignant and premalignant lesions of the oral cavity and esophagus but not keratosis were positive for p16.

Conclusions

Pathological examinations with p16 immunohistochemistry may contribute to an early diagnosis of secondary malignancy after HSCT.

Available only for authorised users

Baker KS, DeFor TE, Burns LJ, Ramsay NK, Neglia JP, Robinson LL: New malignancies after blood or marrow stem cell transplantation in children and adults: incidence and risk factors. J Clin Oncol. 2003, 21: 1352-1358. 10.1200/JCO.2003.05.108.CrossRefPubMed

Demarosi F, Lodi G, Carrassi A, Soligo D, Sardella A: Oral malignancies following HSCT: graft versus host disease and other risk factors. Oral Oncol. 2005, 41: 865-877. 10.1016/j.oraloncology.2005.02.001.CrossRefPubMed

Curtis RE, Metayer C, Rizzo JD, Socié G, Sobocinski KA, Flowers MED, Travis WD, Travis LB, Horowitz MM, Deeg HJ: Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case–control study. Blood. 2005, 105: 3802-3811. 10.1182/blood-2004-09-3411.PubMedCentralCrossRefPubMed

Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socié G, Travis LB, Horowitz MM, Witherspoon RP, Hoover RN, Sobocinski KA, Fraumeni JF, Boice JD: Solid cancers after bone marrow transplantation. N Engl J Med. 1997, 336: 897-904. 10.1056/NEJM199703273361301.CrossRefPubMed

Otsubo H, Yokoe H, Miya T, Atsuta F, Miura N, Tanzawa H, Sato K: Gingival squamous cell carcinoma in a patients with chronic graft-versus-host disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997, 84: 171-174. 10.1016/S1079-2104(97)90065-2.CrossRefPubMed

Mawardi H, Elad S, Correa ME, Stevenson K, Woo S-B, Almazrooa S, Haddad R, Antin JH, Soiffer R, Treister N: Oral epithelial dysplasia and squamous cell carcinoma following allogenic hematopoietic stem cell transplantation: clinical presentation and treatment outcomes. Bone Marrow Transplant. 2011, 46: 884-891. 10.1038/bmt.2011.77.PubMedCentralCrossRefPubMed

Gologan O, Barnes EL, Hunt JL: Potential diagnostic use of p16INK4A, a new marker that correlates with dysplasia in oral squamoproliferative lesions. Am J surg Patol. 2005, 29: 792-796. 10.1097/01.pas.0000163361.40357.b8.CrossRef

Bhatia S, Louie AD, Bhatia R, O’Donnell MR, Fung H, Kashyap A, Krishnan A, Molina A, Nademanee A, Niland JC, Parker PA, Snyder DS, Spielberger R, Stein A, Forman SJ: Solid cancers after bone marrow transplantation. J Clin Oncol. 2001, 19: 464-471.PubMed

Hamadah I, Binamer Y, Alajlan S, Nassar A, Saleh AJM: Squamous cell carcinoma of the lip after allogeneic hematopoietic stem cell transplantation. Hematol Oncol Stem Cell Ther. 2010, 3: 84-88.CrossRefPubMed

10.

Montebugnoli L, Gissi DB, Marchetti C, Foschini MP: Multiple squamous cell carcinoma of the oral cavity in a young patient with graft-versus-host disease following allogeneic bone marrow transplantation. Int J Oral Maxillofac Surg. 2011, 40: 556-558. 10.1016/j.ijom.2010.11.008.CrossRefPubMed

11.

Serdar ZA, Eren PA, Canbakan M, Turan K, Tellioglu G, Gülle S, Ozgezer T, Kara M, Berber I, Titis MI: Dermatologic findings in renal transplant recipients: possible effects of immunosuppression regimen and p53 mutations. Transplant Proc. 2012, 42: 2538-2541.CrossRef

12.

Acay RR, Felizzola CR, Arau´jo NS, Sousa SOM: Evaluation of proliferative potential in oral lichen planus and oral lichenoid lesions using immunohistochemical expression of p53 and Ki67. Oral Oncol. 2006, 42: 475-480. 10.1016/j.oraloncology.2005.09.012.CrossRefPubMed

13.

Singh BB, Chandler FW, Whitaker SB, Forbes-Nelson AE: Immunohistochemical evaluation of bcl-2 oncoprotein in oral dysplasia and carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998, 85: 692-698. 10.1016/S1079-2104(98)90037-3.CrossRefPubMed

14.

Yao L, Iwai M, Furuta I: Correlation of bcl-2 and p53 expression with the clinicopathological features in tongue squamous cell carcinomas. Oral Oncol. 1999, 35: 56-62. 10.1016/S1368-8375(98)00055-4.CrossRefPubMed

15.

Harris SL, Thorne LB, Seaman WT, Hayes DN, Couch ME, Kimple RJ: Association of p16(INK4a) overexpression with improved outcomes in young patients with squamous cell cancers of the oral tongue. Head Neck. 2011, 33: 1622-1627. 10.1002/hed.21650.CrossRefPubMed

16.

Socie G, Scieux C, Gluckman E, Soussi T, Clavel C, Saulnier P, Birembault P, Bosq J, Morinet F, Janin A: Squamous cell carcinomas after allogeneic bone marrow transplantation for aplastic anemia: further evidence of a multistep process. Transplantaion. 1998, 66: 667-670. 10.1097/00007890-199809150-00023.CrossRef

17.

Chen MH, Chang PM, Li WY, Hsiao LT, Hong YC, Liu CY, Gau JP, Liu Jh, Chen PM, Chiou TJ, Tzeng CH: High incidence of oral squamous cell carcinoma independent of HPV infection after allogeneic hematopoietic SCT in Taiwan. Bone Marrow Transplant. 2011, 46: 567-572. 10.1038/bmt.2010.163.CrossRefPubMed

18.

Wang WC, Wu TT, Chandan VS, Lohse CM, Zhang L: Ki-67 and ProExC are useful immunohistochemical markers in esophageal squamous intraepithelial neoplasia. Hum Pathol. 2011, 42: 1430-1437. 10.1016/j.humpath.2010.12.009.CrossRefPubMed

Title: p16 overexpression in malignant and premalignant lesions of the oral and esophageal mucosa following allogeneic hematopoietic stem cell transplantation
Authors: Yasumasa Kakei
Masaya Akashi
Hideki Komatsubara
Tsutomu Minamikawa
Takahide Komori
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Head & Neck Oncology / Issue 1/2012
Electronic ISSN: 1758-3284
DOI: https://doi.org/10.1186/1758-3284-4-38

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Objectives

Case report

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

Knockdown of aberrantly expressed nuclear localized decorin attenuates tumour angiogenesis related mediators in oral cancer progression model in vitro

Reconstruction of scalp defects with the radial forearm free flap

A patient with ulcerated calcifying epithelioma of Malherbe in the pinna: case report

Spinal metastasis in thyroid cancer

Feasibility of recruitment to an oral dysplasia trial in the United Kingdom

Photodynamic therapy in the management of potentially malignant and malignant oral disorders

Keynote webinar | Spotlight on antibody–drug conjugates in cancer